PE20240656A1 - Anticuerpos anti-cd20 y estructuras car-t - Google Patents
Anticuerpos anti-cd20 y estructuras car-tInfo
- Publication number
- PE20240656A1 PE20240656A1 PE2023002858A PE2023002858A PE20240656A1 PE 20240656 A1 PE20240656 A1 PE 20240656A1 PE 2023002858 A PE2023002858 A PE 2023002858A PE 2023002858 A PE2023002858 A PE 2023002858A PE 20240656 A1 PE20240656 A1 PE 20240656A1
- Authority
- PE
- Peru
- Prior art keywords
- antibodies
- car
- structures
- seq
- amino acid
- Prior art date
Links
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 3
- 238000006467 substitution reaction Methods 0.000 abstract 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 abstract 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 abstract 1
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 abstract 1
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 abstract 1
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 abstract 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 abstract 1
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 abstract 1
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 abstract 1
- 206010025323 Lymphomas Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464424—CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the structure of the chimeric antigen receptor [CAR]
- A61K2239/11—Antigen recognition domain
- A61K2239/13—Antibody-based
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Se refiere a anticuerpos anti-CD20 caracterizado porque comprende una region variable de cadena pesada que comprende: (a) una secuencia de CDR1 que comprende dos o menos sustituciones en cualquiera de las secuencias de aminoacidos de las SEQ ID NO: 1 o 4; y/o (b) una secuencia de CDR2 que comprende dos o menos sustituciones en cualquiera de las secuencias de aminoacidos de las SEQ ID NO: 2 o 5; y/o (c) una secuencia de CDR3 que comprende dos o menos sustituciones en cualquiera de las secuencias de aminoacidos de las SEQ ID NO: 3 o 6. Tambien se refiere a que dichos anticuerpos estan en formato CAR-T, multiespecificos. Ademas, se refiere a metodos para producir dichos anticuerpos y estructuras CAR-T, composiciones, composiciones farmaceuticas que comprenden dichos anticuerpos y estructuras CAR-T, y su uso para tratar trastornos que se caracterizan por la expresion de CD20, tales como linfoma no de Hodgkin (NHL), leucemia linfocitica cronica (CLL), entre otros.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163176161P | 2021-04-16 | 2021-04-16 | |
PCT/US2022/025077 WO2022221698A1 (en) | 2021-04-16 | 2022-04-15 | Anti-cd20 antibodies and car-t structures |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20240656A1 true PE20240656A1 (es) | 2024-04-04 |
Family
ID=81585457
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2023002858A PE20240656A1 (es) | 2021-04-16 | 2022-04-15 | Anticuerpos anti-cd20 y estructuras car-t |
Country Status (15)
Country | Link |
---|---|
US (1) | US20240117063A1 (es) |
EP (1) | EP4323403A1 (es) |
JP (1) | JP2024513951A (es) |
KR (1) | KR20230171952A (es) |
CN (1) | CN117337303A (es) |
AU (1) | AU2022259688A1 (es) |
BR (1) | BR112023021225A2 (es) |
CA (1) | CA3215241A1 (es) |
CL (1) | CL2023003073A1 (es) |
CO (1) | CO2023013543A2 (es) |
CR (1) | CR20230525A (es) |
IL (1) | IL306045A (es) |
MX (1) | MX2023012181A (es) |
PE (1) | PE20240656A1 (es) |
WO (1) | WO2022221698A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11873336B2 (en) | 2017-12-22 | 2024-01-16 | Teneobio, Inc. | Heavy chain antibodies binding to CD22 |
JOP20210323A1 (ar) | 2019-06-14 | 2023-01-30 | Teneobio Inc | ارتباط أجسام مضادة ثقيلة السلسلة ومتعددة النوعية بـ cd22 وcd3 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
WO1997034631A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
GB0115256D0 (en) | 2001-06-21 | 2001-08-15 | Babraham Inst | Mouse light chain locus |
NZ538996A (en) | 2002-10-31 | 2008-04-30 | Genentech Inc | Methods and compositions for increasing antibody production |
EP1585768A2 (en) | 2003-01-23 | 2005-10-19 | Genentech, Inc. | Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture |
EP3272770B1 (en) | 2004-07-22 | 2023-12-20 | Erasmus University Medical Center Rotterdam | Method for the production of a vh heavy chain-only antibody in a transgenic mammal and binding polypeptide complex consisting of a dimer of a first chain and a second chain wherein each chain consists of two antigen-specific vh binding domains linked by a dimerisation domain |
US20160355591A1 (en) | 2011-05-02 | 2016-12-08 | Immunomedics, Inc. | Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies |
US20100122358A1 (en) | 2008-06-06 | 2010-05-13 | Crescendo Biologics Limited | H-Chain-only antibodies |
PT2406284T (pt) | 2009-03-10 | 2016-09-29 | Biogen Ma Inc | Anticorpos anti-bcma |
GB0905023D0 (en) | 2009-03-24 | 2009-05-06 | Univ Erasmus Medical Ct | Binding molecules |
US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
CN105384825B (zh) * | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
US11613572B2 (en) | 2016-06-21 | 2023-03-28 | Teneobio, Inc. | CD3 binding antibodies |
WO2018039180A1 (en) | 2016-08-24 | 2018-03-01 | Teneobio, Inc. | Transgenic non-human animals producing modified heavy chain-only antibodies |
US10246514B2 (en) * | 2016-09-12 | 2019-04-02 | The United States Of America, As Represented By The Secretary Of The Navy | Single domain antibodies that bind to human CD20 |
BR122022002481A8 (pt) | 2016-09-14 | 2023-02-07 | Teneobio Inc | Anticorpos biespecíficos de ligação específica para cd3delta-epsilon |
US20220218745A1 (en) * | 2017-12-22 | 2022-07-14 | 2Seventy Bio, Inc. | Multivalent chimeric antigen receptor |
US20220195068A1 (en) * | 2019-04-05 | 2022-06-23 | Teneobio, Inc. | Heavy chain antibodies binding to psma |
-
2022
- 2022-04-15 JP JP2023562540A patent/JP2024513951A/ja active Pending
- 2022-04-15 BR BR112023021225A patent/BR112023021225A2/pt unknown
- 2022-04-15 IL IL306045A patent/IL306045A/en unknown
- 2022-04-15 MX MX2023012181A patent/MX2023012181A/es unknown
- 2022-04-15 CA CA3215241A patent/CA3215241A1/en active Pending
- 2022-04-15 PE PE2023002858A patent/PE20240656A1/es unknown
- 2022-04-15 AU AU2022259688A patent/AU2022259688A1/en active Pending
- 2022-04-15 EP EP22721975.5A patent/EP4323403A1/en active Pending
- 2022-04-15 CR CR20230525A patent/CR20230525A/es unknown
- 2022-04-15 KR KR1020237038039A patent/KR20230171952A/ko unknown
- 2022-04-15 WO PCT/US2022/025077 patent/WO2022221698A1/en active Application Filing
- 2022-04-15 CN CN202280027742.6A patent/CN117337303A/zh active Pending
-
2023
- 2023-09-25 US US18/473,965 patent/US20240117063A1/en active Pending
- 2023-10-13 CO CONC2023/0013543A patent/CO2023013543A2/es unknown
- 2023-10-16 CL CL2023003073A patent/CL2023003073A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
CR20230525A (es) | 2024-02-19 |
BR112023021225A2 (pt) | 2023-12-19 |
AU2022259688A1 (en) | 2023-10-05 |
CO2023013543A2 (es) | 2023-10-30 |
MX2023012181A (es) | 2023-12-15 |
WO2022221698A1 (en) | 2022-10-20 |
CN117337303A (zh) | 2024-01-02 |
CL2023003073A1 (es) | 2024-04-19 |
CA3215241A1 (en) | 2022-10-20 |
IL306045A (en) | 2023-11-01 |
JP2024513951A (ja) | 2024-03-27 |
EP4323403A1 (en) | 2024-02-21 |
US20240117063A1 (en) | 2024-04-11 |
KR20230171952A (ko) | 2023-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20240656A1 (es) | Anticuerpos anti-cd20 y estructuras car-t | |
CR20210326A (es) | Moléculas agonistas de unión al antígeno cd28 que actúan sobre el tumor | |
PE20190356A1 (es) | Receptores quimericos y metodos de uso de los mismos | |
CL2019001740A1 (es) | Novedoso conjugado de amanitina. | |
PE20091193A1 (es) | Proteinas humanas de union a antigenos del gm-csf | |
AR095432A1 (es) | Proteínas de unión a antígeno | |
AR106184A1 (es) | Proteínas de unión a pd-1 y sus métodos de uso | |
ZA201804654B (en) | Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates | |
FI3389699T3 (fi) | Kimeerisiä ja humanisoituja humaaneja monoklonaalisia ctla4-vasta-aineita ja niiden käyttötapoja | |
RU2018112649A (ru) | Композиция для лечения рака, объединяющая анти-cd26 антитело и другое противораковое средство | |
PE20181323A1 (es) | Terapias de combinacion para enfermedades malignas hematologicas con anticuerpos anti-cd38 e inhibidores de survivina | |
EA202192736A1 (ru) | Антитела, содержащие только тяжелые цепи, которые связываются с псма | |
MX2019006362A (es) | Una combinacion de inmunoconjugado y anticuerpo para usarse en el tratamiento de cancer. | |
AR072897A1 (es) | Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5 | |
EA201890158A1 (ru) | Антитела против ntb-a и связанные композиции и способы | |
PE20140196A1 (es) | Anticuerpos anti-cd37 | |
AR073425A1 (es) | Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente la cd38 y la citarabina | |
PE20141019A1 (es) | Nuevos inmunoconjugados | |
PE20120079A1 (es) | Moleculas de anticuerpos mejoradas | |
BR112021024956A2 (pt) | Anticorpos multiespecíficos de cadeia pesada que se ligam a cd22 e cd3 | |
EA201491571A1 (ru) | МОДИФИЦИРОВАННЫЕ БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА IgG4 С АСИММЕТРИЧНОЙ ПОСЛЕДОВАТЕЛЬНОСТЬЮ | |
MX2013009151A (es) | Inmunoterapia mejorada. | |
PE20161311A1 (es) | Anticuerpos especificos del receptor del factor 1 de crecimiento similar a la insulina y usos de los mismos. | |
PE20230464A1 (es) | Union de anticuerpos multiespecificos a bcma | |
MX2023005081A (es) | Anticuerpos multiespecificos para dirigirse a cd28 y pd-l1 y metodos de uso de los mismos. |